Trials / Completed
CompletedNCT04601298
The Risk Stratification of Papillary Thyroid Cancer With AUS/FLUS by FNA
The Risk Stratification of Papillary Thyroid Cancer With Bethesda Category III（AUS/FLUS）by Thyroid Fine-Needle Aspiration（FNA）Could be Assisted by Tumor Size for Precision Treatment
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 290 (actual)
- Sponsor
- Shanghai 10th People's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 77 Years
- Healthy volunteers
- Not accepted
Summary
Purpose: To investigate the clinical characteristics of papillary thyroid cancer (PTC) with Bethesda category III (AUS/FLUS) by fine needle aspiration (FNA) and to assisted the precision treatment. Methods:A total of 290 patients who underwent thyroidectomies or thyroid lobectomies from August 2015 to September 2020, following a diagnosis of Bethesda category III (AUS/FLUS) from preoperative thyroid FNA were investigated. Groups: In order to investigate the clinopathologic characteristics, the patients, were grouped according to Cytology,Gender, Tumor size.
Detailed description
Purpose: To investigate the clinical characteristics of papillary thyroid cancer (PTC) with Bethesda category III (AUS/FLUS) by fine needle aspiration (FNA) and to assisted the precision treatment. Methods:A total of 1739 cases diagnosed with Bethesda category III (AUS/FLUS) by FNA from August 2015 to September 2020 were reviewed, and 523 patients received thyroidectomy or lobectomy. 290 patients were diagnosed with PTC and investigated retrospectively. Groups: In order to investigate the clinopathologic characteristics, the patients, were grouped according to Cytology,Gender, Tumor size.as follows:AUS and FLUS\&AUS/FLUS;male and female; tumor size≤1cm and\>1cm.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | — |
Timeline
- Start date
- 2015-08-01
- Primary completion
- 2020-09-30
- Completion
- 2020-09-30
- First posted
- 2020-10-23
- Last updated
- 2021-03-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04601298. Inclusion in this directory is not an endorsement.